Title: 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
Abstract: // Shiming Zang 1, * , Guoqiang Shao 1, * , Can Cui 1 , Tian-Nv Li 2 , Yue Huang 3 , Xiaochen Yao 1 , Qiu Fan 1 , Zejun Chen 4 , Jin Du 5 , Ruipeng Jia 6 , Hongbin Sun 6 , Zichun Hua 7 , Jun Tang 8 , Feng Wang 1 1 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China 2 Department of Nuclear Medicine, PET Centre, No. 1 Hospital Affiliated to Nanjing Medical University, Nanjing 210029, China 3 Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China 4 Department of Nuclear Medicine, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China 5 Department of Technology Development, China Isotope Radiation Corporation, No. 1 Nansixiang, Sanlihe, West District, Beijing 100045, China 6 Department of Urology, Nanjing Medical University, Nanjing 210006, China 7 The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing 210006, China 8 Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China * These authors have contributed equally to this work Correspondence to: Feng Wang, email: [email protected] Hongbin Sun, email: [email protected] Keywords: treatment-naïve prostate cancer, prostate-specific membrane antigen, metastatic castrate-resistant prostate cancer, staging, risk stratification Received: July 22, 2016 Accepted: December 27, 2016 Published: January 17, 2017 ABSTRACT We evaluated the clinical utility of 68 Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68 Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68 Ga-PSMA-11 images. Only 3 patients with stable mCRPC after chemotherapy were negative for PSMA. The sensitivity, specificity and accuracy of 68 Ga-PSMA-11 imaging were 97.3%, 100.0% and 97.5%, respectively. The maximum standardized uptake (SUV max ) of prostatic lesions was 17.09 ± 11.08 and 13.33 ± 12.31 in treatment-naïve PCa and mCRPC, respectively. 68 Ga-PSMA-11 revealed 105 metastatic lymph nodes in 15 patients; the SUV max was 16.85 ± 9.70 and 7.54 ± 5.20 in treatment-naïve PCa and mCRPC, respectively. 68 Ga-PSMA-11 PET/CT also newly detected visceral metastasis in 9 patients (22.5%) and bone metastasis in 29 patients (72.5%). 68 Ga-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naïve PCa, as well as improved sensitivity for detection of lymph node and remote metastasis.